Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

Scott M. Schuetze, Vanessa Bolejack, Edwin Choy, Kristen N. Ganjoo, Arthur P. Staddon, Warren A. Chow, Hussein A. Tawbi, Brian L. Samuels, Shreyaskumar R. Patel, Margaret von Mehren, Gina D'Amato, Kirsten M. Leu, David M. Loeb, Charles A. Forscher, Mohammed M. Milhem, Daniel A. Rushing, David R. Lucas, Rashmi Chugh, Denise K. Reinke, Laurence H. Baker

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

BACKGROUND: Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid sarcoma, and solitary fibrous tumor (SFT) are malignant tumors that are relatively resistant to chemotherapy and for which more effective drug therapy is needed. METHODS: The 5 listed subtypes were enrolled into a single indolent sarcoma cohort in a phase 2 study of dasatinib using a Bayesian continuous monitoring rule for enrollment. The primary objective was to estimate the 6-month progression-free survival (PFS) rate according to the Choi criteria with a target of ≥50%. Cross-sectional imaging was performed before the start of treatment, every 2 months for 6 months, and then every 3 months during treatment. The 2- and 5-year survival rates were determined. RESULTS: One hundred sixteen patients were enrolled within 45 months, and 109 began treatment with dasatinib. The 6-month PFS rate and the median PFS were 48% and 5.8 months, respectively. The PFS rate at 6 months was highest with ASPS (62%) and lowest with SFT (30%). More than 10% of the patients with ASPS, CS, or chordoma had stable disease for more than 1 year. Collectively, for all 5 subtypes, the 2- and 5-year overall survival rates were 44% and 13%, respectively. An objective response was observed in 18% of the patients with CS or chordoma. CONCLUSIONS: Dasatinib failed to achieve control of sarcoma growth for at least 6 months in more than 50% of the patients in this trial according to the Choi tumor response criteria. An objective tumor response and prolonged stable disease was observed in >10% of patients with CS or chordoma. Cancer 2017;90–97.

Original languageEnglish (US)
Pages (from-to)90-97
Number of pages8
JournalCancer
Volume123
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Keywords

  • Bayesian
  • chemotherapy
  • Choi
  • chondrosarcoma
  • chordoma
  • dasatinib
  • phase 2
  • sarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor'. Together they form a unique fingerprint.

  • Cite this

    Schuetze, S. M., Bolejack, V., Choy, E., Ganjoo, K. N., Staddon, A. P., Chow, W. A., Tawbi, H. A., Samuels, B. L., Patel, S. R., von Mehren, M., D'Amato, G., Leu, K. M., Loeb, D. M., Forscher, C. A., Milhem, M. M., Rushing, D. A., Lucas, D. R., Chugh, R., Reinke, D. K., & Baker, L. H. (2017). Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer, 123(1), 90-97. https://doi.org/10.1002/cncr.30379